The neural substrate of apathy in persons at high risk for psychosis - a PET study

Withdrawn

• Conditions: apathy; psychosis; 10039628

• Registration Number: NL-OMON43208
• Lead Sponsor: eurowetenschappen, sectie Cognitieve Neuropsychiatrie

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 23 April 2024

Recruitment & Eligibility

• Status: Withdrawn
• Sex: Not specified
• Target Recruitment: 36

Inclusion Criteria

Individuals with an UHR state:
At least 18 years of age
UHR state according to the CAARMS interview (administered within 6 months before scanning)
The two UHR-groups will be matched on age, sex, education, levels of depressive symptoms, medication and handedness
Written Informed Consent;Healthy controls:
At least 18 years of age
Matched to UHR group on age, sex, education, levels of depressive symptoms and handedness
Absence or low levels of apathy
Written Informed Consent

Exclusion Criteria

Individuals with an UHR state:
Use of antipsychotics;Healthy controls:
High level of apathy (AES>26)
Presence of a psychiatric disorder, in present or past (based on the mini-SCAN).;All subjects:
Presence of a neurological or substance dependence disorder
Visual or hearing problems that cannot be corrected
Insufficient knowledge of the Dutch language
Inability to undergo cognitive testing;Additional criteria, due to the use of neuroimaging (all subjects):
(Suspected) pregnancy (performed by pregnancy test)
Claustrophobia
The refusal to be informed (by notifying the participant's physician) of structural brain
abnormalities that could be detected during the experiment
MR incompatible implants in the body (such as ear prostheses or other metal implants)
Risk of having metal particles in the eyes
Tattoos containing red pigments that form a safety risk
Participation in a scientific research study during the past year involving radiation
Smoking or other forms of nicotine intake 24 hours prior to the study

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The main study parameter will be the binding potential of [11C]-raclopride..</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>n.a.</p><br>